Company profile
SMITH & NEPHEW PLC
NYSE:SNNIndustrial Specialties
Drug pipeline (21)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| AMINOPHYLLINE | approved | — | 0 | — |
| Clindamycin Phosphate | approved | — | 0 | — |
| Cyanocobalamin | approved | — | 0 | — |
| Dopamine Hydrochloride | approved | — | 0 | — |
| Droperidol | approved | — | 0 | — |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02718625 | phase4 | terminated | 2016-08-01 | 2017-03-09 | Smith & Nephew, Inc. | Study of SANTYL® vs Hydrogel (SoloSite®) for Pressure Ulcers |
| NCT02716519 | phase4 | withdrawn | 2016-08-01 | 2018-12-01 | Smith & Nephew, Inc. | Use of Santyl Within an Accountable Care Organization |
| NCT02581488 | phase4 | completed | 2015-10-01 | 2017-01-12 | Smith & Nephew, Inc. | Use of Santyl in Diabetic Foot Ulcers |
FDA applications (76)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| ANDA 062507 | ANDA | SOLOPAK LABORATORIES INC | ||||
Loading… | ||||||
| ANDA 062605 | ANDA | SOLOPAK LABORATORIES INC | ||||
Loading… | ||||||
| ANDA 062819 | ANDA | SOLOPAK LABORATORIES INC | ||||
Loading… | ||||||
| ANDA 062852 | ANDA | SOLOPAK LABORATORIES INC | ||||
Loading… | ||||||
| ANDA 070011 | ANDA | SMITH AND NEPHEW SOLOPAK DIV SMITH AND NEPHEW | ||||
Loading… | ||||||